Blog
RSS FeedPosted by Michael Wonder on 08 Jun 2023
Congress’ misguided plan to ban QALYs
8 June 2023 - Paying for health care is a challenge for many Americans, but the House of Representatives is on ...
Posted by Michael Wonder on 05 Jun 2023
ICER proposes updates to value assessment framework methods and procedures
5 June 2023 - Proposed updates reflect experience with current framework, benchmarking with other health technology assessment groups, and external stakeholder ...
Posted by Michael Wonder on 03 Jun 2023
America will struggle to pay for ultra-expensive gene therapies
1 June 2023 - The drugs may force reform to Medicaid. ...
Posted by Michael Wonder on 29 May 2023
A review of HTA guidelines on societal and novel value elements
25 May 2023 - Health technology assessment organisations vary in terms of how they conduct assessments. ...
Posted by Michael Wonder on 25 May 2023
ICER publishes final evidence report on treatments for non-alcoholic steatohepatitis
25 May 2023 - Independent appraisal committee narrowly voted that currently available evidence for resmetirom is adequate to demonstrate a net ...
Posted by Michael Wonder on 15 May 2023
ICER to assess treatment for pulmonary arterial hypertension
15 May 2023 - Report will be subject of Midwest CEPAC meeting in December 2023; draft scoping document open to ...
Posted by Michael Wonder on 24 Apr 2023
NICE collaborates with international partner agencies to streamline the confidential marking process
24 April 2023 - NICE, the Canadian Agency for Drugs and Technologies in Health and the US’s Institute for Clinical and ...
Posted by Michael Wonder on 19 Apr 2023
ICER publishes white paper evaluating best practices and potential reforms for white bagging, brown bagging, and site of service policies that seek to address high markup in drug prices
19 April 2023 - White bagging, brown bagging, and site of service policies developed by payers can reduce significant markup costs ...
Posted by Michael Wonder on 18 Apr 2023
Cost effectiveness thresholds used by study authors (1990-2021)
18 April 2023 - For decades, many US authors of cost effectiveness analyses referenced a common benchmark or threshold—$50 000 per quality-adjusted ...
Posted by Michael Wonder on 17 Apr 2023
ICER publishes final evidence report on lecanemab for Alzheimer’s disease
17 April 2023 - Using best estimates from current data, ICER analyses suggest lecanemab would achieve common thresholds for cost-effectiveness if ...
Posted by Michael Wonder on 14 Apr 2023
Throwing the baby out with the bath water: Congress considers banning the QALY
3 April 2023 - In late March, the House Committee on Energy and Commerce advanced H.R. 485 - Protecting Health ...
Posted by Michael Wonder on 13 Apr 2023
ICER publishes evidence report on treatments for non-alcoholic steatohepatitis
13 April 2023 - Current evidence suggests that resmetirom would achieve common thresholds for cost effectiveness if priced between $39,600–$50,100 per ...
Posted by Michael Wonder on 12 Apr 2023
ICER releases draft evidence report on gene therapies for sickle cell disease
12 April 2023 - Public comment period now open until 9 May 2023; Requests to make oral comment during public ...
Posted by Michael Wonder on 11 Apr 2023
ICER publishes 2023 research protocol for assessing unsupported price increases on prescription drugs
11 April 2023 - Annual unsupported price increase report to be published on December 12. ...
Posted by Michael Wonder on 16 Mar 2023
ICER publishes white paper on using comparative effectiveness research to address prescription drug spending in California
16 March 2023 - State policy makers and purchasers in California are uniquely positioned to further integrate comparative effectiveness research ...